Astellas Launches First Direct-to-Consumer Campaign for IZERVAY, Highlighting Its Potential to Slow Geographic Atrophy Progression

IZERVAY Approval:
IZERVAY (avacincaptad pegol intravitreal solution) was approved by the U.S. FDA on August 4, 2023, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Clinical Trial Results:
The GATHER2 Phase 3 clinical trial demonstrated that IZERVAY continued to reduce the rate of GA lesion growth for both monthly and every-other-month dosing compared to sham through 2 years of treatment.

DTC Campaign:
Astellas Pharma has launched its first direct-to-consumer (DTC) campaign for IZERVAY, focusing on its potential to slow the progression of AMD and prevent GA, extending people’s ability to see clearly as they age.

Target Audience:
The campaign targets patients who may be at risk of developing GA, estimated to be up to 1.5 million people in the U.S..

Regulatory Update:
The U.S. FDA has accepted Astellas' supplemental New Drug Application (sNDA) to include positive 2-year data in the U.S. Prescribing Information for IZERVAY, with a target action date of November 19, 2024.